• Explore /
  • Poster
  • / Real-world time-to-castration resistance (CR) among patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) initiating apalutamide (APA), enzalutamide (ENZ), or abiraterone acetate (ABI) from an oncology database.

Real-world time-to-castration resistance (CR) among patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) initiating apalutamide (APA), enzalutamide (ENZ), or abiraterone acetate (ABI) from an oncology database.

Abstract Poster

Authors

null

Benjamin H Lowentritt

Chesapeake Urology, Towson, MD

Benjamin H Lowentritt , Carmine Rossi , Shawn Du , Erik Muser , Frederic Kinkead , Dexter Waters , Patrick Lefebvre , Dominic Pilon , Neeraj Agarwal

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Quality of Care/Quality Improvement and Real-World Evidence

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr 65)

DOI

10.1200/JCO.2023.41.6_suppl.65

Abstract #

65

Poster Bd #

B19

Abstract Disclosures

Similar Posters

First Author: Alicia K. Morgans

Poster

2023 ASCO Genitourinary Cancers Symposium

Real-world use of darolutamide, enzalutamide, and apalutamide for non-metastatic castration-resistant prostate cancer (DEAR).

Real-world use of darolutamide, enzalutamide, and apalutamide for non-metastatic castration-resistant prostate cancer (DEAR).

First Author: Daniel J. George

First Author: Mehmet Asim Bilen

First Author: Naoki Fujita